Technology inventions help people around the world live longer and healthier, spur our economy and solve our social problems. As the Co-founder and CEO of a Robotic HealthTech start-up with the focus to tackle the problem of healthcare accessibility and improve the quality of life of the disabled, not only do we design and develop affordable robotic products for physical rehabilitation, but also provide solutions to tackle emerging problems in the elderly and healthcare industries.
For instances, we enable automatic tele-visit in elderly homes and hospital wards with robots during the outbreak of the pandemic in Hong Kong. In order to improve the effectiveness of doll therapy on elderly with dementia, we design and produce an interactive companion robot in collaboration with professional therapists and NGOs. With the team’s effort, I was recognised as a Forbes 30 Under 30 honouree in 2021 and Gen.T by Tatler Asia in 2020.Social innovation exists to fill the gaps of the existing human systems. Apart from developing advanced technology from top-down approach, our team engage directly with users and customers to understand their feedback on our products as well as their needs for new solutions. This is an important step to convert the advanced technology into real-life applications which enables us to strive to achieve excellence.
Dr Ricky Chiu has been recognised as being one of the top leaders in the biotechnology field in Hong Kong. He is driven by his passion to serve humanity. Born in Hong Kong and trained in the United States, he has developed a proprietary sample preparation technology which significantly increases the speed and accuracy of diagnostic testing, enabling earlier detection of cancers and infectious diseases and reducing the excess deaths associated with these diseases.
As COVID-19 spread in early 2020, Dr Chiu’s commitment to help combat the pandemic was realised through a series of highly accurate COVID-19 diagnostic products he and his team at PHASE Scientific developed. He also advocated continually for the use of rapid antigen test in the fourth and fifth waves of the pandemic to halt the hidden virus chains in the community, supported the Government’s mass distribution of RATs, and donated RATs for needy organisations, thereby helping Hong Kong return to normalcy gradually.
Dr Chiu is dedicated to promoting a sustainable world for tomorrow. The PHASE Scientific team will continue to focus on diagnostic innovations to assist in the detection of different diseases. Additionally, they will implement smart manufacturing processes and incorporate the use of biobased materials to improve the production efficiency and environmental friendliness of their end products.
Having engaged in information technology since 1990s, Dr. Tenny Lam (PolyU DBA) had served as the senior management of MNCs for many years. In recent years, he took over his family business of a conventional chemical manufacturer and has been determined to leverage his rich experience in innovative technology to drive reform and pursue technology breakthroughs.
In 2019, Tenny met Professor Li Pei at PolyU, who has been dedicated to the research of core-shell nanoparticles. Upon exchange, he learned that the innovation can make breakthroughs possible in the application of biological materials. However, the technology has not been converted to products due to the absence of a production base and commercialisation strategy.
They leverage each other’s strengths and decided to find a Bio-Tech startup to recycle bio-based materials and applications to provide greener and safer materials to address the sustainable global challenges.
During the company startup stage, they were in the COVID-19 pandemic. People are more concerned about hygiene than ever. However, commercially available antimicrobial solutions predominantly contain heavy metals and chemicals that may pose health risks upon prolonged exposure and contaminating water and other resources. In light of this, they invented a bio-based long lasting anti-microbial coating that has multiple features such as no release of toxic chemicals; no toxic chemicals leaked into the ecosystem; prolonged protection, and recycling bio-materials.
The team is developing the next generation of edible coating for fruit shelf-life extension to reduce food loss and infection risk during the logistic and delivery stage.
Ms Juliana Lam is the Founder and President of INNOTIER. With “Business with a Purpose” as the company’s core principle and ESG as the brand’s values, she has created several innovative anti-viral products under the new normal. Under the short span of 2 years, INNOTIER has been granted with 4 patents, including the silver yarn fabric and UVC disinfection system, and has since worked with numerous international brands and has accomplished remarkable achievements such as being recognised as a Certified Sustainable Development Corporation (CSDC) presented by UNESCO.
Backed up by two 100% owned factories, Juliana has incorporated INNOTIER’s 3 pillars, “Best hygiene Technologies x Sustainability x Lifestyle Fashion” to be the first to develop a series of anti-viral & earth-friendly lifestyle products, such as apparel, disinfection bags, masks and gloves etc. Most notably, INNOTIER’s “Champion series” silver-woven anti-viral products have been proven to be able to eliminate 99% of viruses instantly ON CONTACT permanently. Their enduring feature can hugely reduce the one-time pandemic disposables.
Juliana is also the founder of Julius Group, with 60 years of family manufacturing experience in gloves and accessories. Julius Group is a forward-thinking company with strong beliefs in transforming the conventional manufacturing business with ESG as their core values. With the vertical setup from manufacturing to retailing, Juliana has used this to her advantage and has worked tirelessly to establish her business in the sustainability industry.
Dr. William Lee is a Co-founder of i2Cool Limited. I2Cool limited is a start-up with a vision to achieve zero-carbon emission for the built environment. William spares no effort to develop novel technologies for sustainability and carbon neutrality. The signature electricity-free cooling paint can effectively reduce electricity consumption and the energy saving can reach 40%. The electricity-free cooling paint won Gold with Congratulations of the Jury in Inventions Geneva Evaluation Days 2021.
William leads I2Cool to receive a lot of awards and funds such as Start-up Award Winner, Idea Stage, Climate Action Recognition Scheme, HK Tech 300 Seed Fund, Ideation, Incubation and Acceleration Programmes (previously known as STEP), Hong Kong Science and Technology Parks, “Maker in China” SME Innovation and Entrepreneurship Global Contest, Hong Kong Chapter, Maker in China” SME Innovation and Entrepreneurship Global Contest, Global Final, HKTech 300 Angel Fund. The electricity-free cooling paint has been used in trials by different parties both locally and internationally. By now, the surface area of electricity-free cooling paint has reached ~10,000 ft2, which contributes to ~23,000 kWh energy saved and ~14,000 kg carbon emissions reduced in Hong Kong. By demonstrating my novel energy-saving inventions to the public via the different platforms, a great sense of environmental protection and living wellness could be raised among different sectors of society, promoting the goal of carbon neutrality.
When Kelvin first arrived in Hong Kong back in 2008, investment was not particularly a popular phrase to the general public thanks to the financial crisis. Seven years later, as the vice president at Deutsche Bank Hong Kong, Kelvin felt the quality of traditional wealth management still left a lot to be desired, and they were not accessible by customers outside of private banking. At that moment Kelvin decided to leave the corporate world behind and co-founded AQUMON with Doctor Don Huang, with one goal in mind – to empower everyday investor to participate in wealth creation and bring about real social progress.
Fast forward to today, Kelvin is now managing a fast-growing company with over 100 staff in Hong Kong and Mainland China, with three rounds of successful fundraising (including Alibaba’s Entrepreneurs Fund, Lenovo and HKUST etc.). By leveraging smart technology and algorithm-based investment solutions, AQUMON is now the leading WealthTech player in the Greater Bay Area. Kelvin is also an appointed member of the FinTech Advisory Group at the Securities and Futures Commission and continues to push on the development and transformation in Hong Kong, and empowering every investor.
As a first-time entrepreneur, being able to create a company with meaningful impact has always been my number goal. With Great Bay Bio, an innovative AI enabled bioprocessing platform, we can really achieve this goal via multiple dimensions:
• Accelerating drug development – GBB is the first company in the world implementing AI in Bioprocessing/biomanufacturing. Our technology can accelerate biologic drug and other bio-product development, enabling faster access of life-saving products to patients.
• ESG – Synthetic biology is said to be the next scientific revolution with profound positive impact on our environment. GBB’s technology aids the commercialsation of scientific discovery of this field, allowing important products, such as culture meat, to hit market earlier and at an affordable price point.
• HK I&T Ecosystem – The boom of HK’s biotech start-up scene is unprecedented. However, an ecosystem needed to support a sustainable growth of the industry is still lacking. GBB is an important addition to the HK biotech ecosystem, enabling local startups to scale up manufacturing of their biotech discoveries.
In the short 3 years since founding, GBB has raised over US$30M from top institutional investors, including TigerJade, Hillhouse, AEF, and a large MNC. The company currently has a commercial reach of over 100+ biotech companies. Finally, GBB is part of 3 top accelerators (Nvidia, Merck and Microsoft), and won various innovation awards in the GBA.
Recognised as one of world’s most outstanding and highly-cited clinician-scientists from the Chinese University of Hong Kong, Prof Siew Ng’s discoveries have revolutionised human health. By using a tiny stool sample, she decodes the trillions of bacteria DNA inside your gut and utilizes AI-driven algorithms to predict risk of diseases.
Entrepreneur Siew Ng had envisioned a world where chronic diseases and cancers can be detected earlier when treatment can be more effective, and solutions can be provided in a faster and safer way. Today, she is Director of Microbiota I-Center (MagIC), a world-class HKSAR Government funded Microbiome R&D center. She co-founded GenieBiome (G-Niib) Ltd with Prof Francis Chan and they are redefining human health with microbiome solutions.
In under 18 months, she has launched 3 novel diagnostic and therapeutic products in Hong Kong, Mainland China and Southeast Asia. Used by millions of people globally, her immunity formula is tailored for Asians and has benefitted the general public at times of the COVID-19 pandemic.
In recognition of her achievements, she was awarded Croucher Professor of Medical Sciences and Gold Medal Awards at International Inventions of Geneva 2022.
“Health is life’s greatest asset. My dream is to bring hope and health to our next generation,” Siew says.
Ivy has 15 years of regional management experience in several Fortune Global 100 companies, including ICT, cloud services & the logistics industry. Most recently held various leadership roles in program delivery, client implementations and compliance. She is also an ISO 9001 auditor, awarded as 2021 Deloitte Tech Fast Female Award Winner and a member of the Hong Kong Logistics Development Council since 2021.
Ivy also actively participates in various talent training programmes, such as the Technology Leaders Of Tomorrow Programme(TLT) and DeepTech Talents Training Programme(DTT) held by the Hong Kong Science Park, to vigorously support and attract talents who are interested in innovation and technology – activating the logistics industry with technology, making the tradition younger.
William Yeung is a Fellow of the Society of Actuaries with solid experience in digital commerce and insurtech applications. He is the co-founder & CEO of MediConCen Limited, which is an insurtech company which utilises blockchain to automate insurance claim and the company launched the first-in-Asia blockchain medical ecosystem with leading insurers.
He was appointed Director, Digital Commerce at FWD and he has co-founded FWD’s digital insurance platform. He then joined ZhongAn Technologies International as Founding Member helping ZhongAn to develop business outside China.
He is co-inventor of 1 Blockchain design patent and 1 medical consultation via hardware patent. Under his leadership, MediConCen is formed with only USD0.3m capital and he convinced ex-Chief Marketing Officer and ex-CEO of insurer to join. MediCenCen launched with the first insurer client in just few months. MediConCen enables insured to use the insurance in a cardless, paperless and cashless basis. The blockchain technology eliminates the need of reconciliation of results and allows automation to be done to the extreme with all parties trusting the results.
Scaling the team from 4 ppl to 28 ppl in 4 years, contracted with 13 insurers and raised US$5.6m to date. William has built a strong tech team and also contributed back to the world’s development of blockchain technology through code contribution. In fact, MediConCen is top 10 contributors to Linux Hyperledger among Greater China in 2020Q2.